Phase IV
Anesthesia and Non-small Cell Lung Cancer Recurrence
- Study IRB#:2000041190
- Last Updated:06/23/2026
There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials.
- Age19 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Joanna Lipson
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Inclusion Criteria
- American Society of Anesthesiologists physical status (ASA) Ⅰ-Ⅲ
- The Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Lung resection surgery (segmentectomy, lobectomy, bilobectomy, pneumonectomy; video-assisted, robot-assisted, or open) with curative intent for NSCLC (clinical Tumor, Node, Metastasis (TNM) stage Ⅰ- ⅢA).
Exclusion Criteria
- Distant metastasis or malignant tumor in other organs that according to the attending surgeon is not in long-term remission
- Severe neurologic conditions
- Severe hepatic disease (Child-Pugh classification C)
- Renal failure requiring renal replacement therapy
- History of anesthesia and/or surgery within 1 yr
- Previous surgery due to lung cancer (except diagnostic biopsies)
- Contraindications to any study medication (history of allergy, hypersensitivity reaction, or any other contraindication)
- Planned joint extrapulmonary procedure
- Surgery under cardiopulmonary bypass or extracorporeal membrane oxygenation
- Postoperative sedation
- Pregnancy, or lactation
- Patient refusal.
